KCNQ2 Developmental and Epileptic Encephalopathy Market Research Report 2025-2035, Competitive Analysis of Biohaven, Xenon Pharma, Lundbeck, Praxis Precision Medicines, NeuShen Therapeutic...
Biohaven Ltd. Common Shares (BHVN)
Last biohaven ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Yahoo! Finance
investment in channelopathy therapeutics, and improved pediatric neurology care. Regulatory support for orphan drugs and better reimbursement policies enhance treatment availability. Challenges include limited patient populations and high developmental drug costs. Opportunities arise from AI diagnostics and telehealth platforms, with major players like Biohaven and Xenon Pharmaceuticals investing in novel therapies. The market is projected to expand through 2035, driven by genomics innovation and global awareness. Dublin, April 28, 2026 (GLOBE NEWSWIRE) -- The "KCNQ2 Developmental and Epileptic Encephalopathy Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The growth of the KCNQ2 Developmental and Epileptic Encephalopathy Market is primarily driven by increased adoption of next-generation sequencing for early genetic identification, heightened R&D investment in channelopathy-focused therap
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven (BHVN) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BHVN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "strMarketBeat
- Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating [Yahoo! Finance]Yahoo! Finance
- Biohaven (BHVN) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BHVN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "strong sell" toMarketBeat
- Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026 [Seeking Alpha]Seeking Alpha
- Why Biohaven Stock Crushed it on Monday [Yahoo! Finance]Yahoo! Finance
BHVN
Earnings
- 3/2/26 - Beat
BHVN
Sec Filings
- 3/19/26 - Form 4
- 3/13/26 - Form DEFA14A
- 3/13/26 - Form DEF
- BHVN's page on the SEC website